Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Company Deals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Fineline Cube May 20, 2026
Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Fineline Cube May 20, 2026
Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Fineline Cube May 20, 2026
Company Drug

Lundbeck’s Eptinezumab Launches in Boao Lecheng for Migraine Treatment

Fineline Cube Nov 11, 2022

Lundbeck’s (FRA: LDBB) Eptinezumab has been launched in the Boao Lecheng International Medical Tourism Zone,...

Company Deals Digital

Novartis Partners with Alibaba Health to Enhance Patient Medication Accessibility

Fineline Cube Nov 11, 2022

The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Swiss...

Company Drug

RemeGen’s Telitacicept Set for Breakthrough Therapy Designation in Myasthenia Gravis

Fineline Cube Nov 11, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based RemeGen Co., Ltd’s (HKG: 9995,...

Company Deals

Harbour BioMed and Moderna Ink Licensing Deal for Oncology Immunotherapies

Fineline Cube Nov 11, 2022

Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands,...

Company Drug

CStone’s PD-L1 Inhibitor Sugemalimab Achieves Primary Endpoint in Gastric Cancer Study

Fineline Cube Nov 11, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has announced that its GEMSTONE-303 study for the programmed death-ligand...

Company Drug

BeiGene’s Brukinsa Receives Marketing Approval in Brazil

Fineline Cube Nov 11, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that it has...

Company Drug

Fujian Cosunter Receives Multiple Patents for Cancer and Hepatitis Drugs

Fineline Cube Nov 11, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the receipt of multiple patents...

Company Drug

Sinocelltech’s SCTV01E Vaccine Receives NMPA Approval for Phase II Study

Fineline Cube Nov 11, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received approval from the...

Company Drug

3SBio’s Thrombopoietin Study in Pediatric ITP Reaches Primary Endpoint

Fineline Cube Nov 10, 2022

China-based 3SBio Inc. (HKG: 1530) has announced that its multi-center, randomized, double-blind, placebo-controlled study assessing...

Company Deals

Zenas BioPharma Completes $118M Series B Financing to Advance Obexelimab

Fineline Cube Nov 10, 2022

Autoimmune disease drug developer Zenas BioPharma, which is based in the US and China, has...

Company Drug

LianBio Initiates Phase I Study of SHP2 Inhibitor BBP-398 in China

Fineline Cube Nov 10, 2022

Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study...

Company Deals

Innovex Medical Files for IPO in Hong Kong to Boost Product Development

Fineline Cube Nov 10, 2022

Innovex Medical Co., Ltd, a non-vascular interventional surgery solutions provider based in Shanghai, has filed...

Company Drug

NMPA Conditionally Approves Yingli Pharma’s Linperlisib for Lymphoma

Fineline Cube Nov 10, 2022

The National Medical Products Administration (NMPA) website indicates that linperlisib, a Category 1 anti-tumor drug,...

Company Drug

Ascentage Pharma Gains CDE Approval for Phase I Study of APG-5918

Fineline Cube Nov 10, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center...

Policy / Regulatory

China Releases 14th Five-Year Plan for National Health Informatization

Fineline Cube Nov 10, 2022

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and the National Bureau...

Company

Zai Lab Reports 33% YOY Revenue Growth in Q3 2022

Fineline Cube Nov 10, 2022

Chinese biopharmaceutical firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q3 2022 earnings...

Company Deals

GSK Partners with CASPC to Advance HIV Sustained Care Advocacy in China

Fineline Cube Nov 10, 2022

The 5th China International Import Expo (CIIE) saw the unveiling of a partnership between GlaxoSmithKline...

Company Drug

3SBio Receives NMPA Review for Pediatric ITP Thrombopoietin Filing

Fineline Cube Nov 10, 2022

China-based 3SBio Inc. (HKG: 1530) has announced that the National Medical Products Administration (NMPA) has...

Company Deals

Boston Scientific Partners with Omron for Atrial Fibrillation Management

Fineline Cube Nov 10, 2022

US-based Boston Scientific Corporation (NYSE: BSX) has announced a partnership with Japan-based Omron Healthcare at...

Company Deals

Takeda Partners with AWS and Accenture to Launch Innovation Incubator at CIIE

Fineline Cube Nov 10, 2022

The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Takeda...

Posts pagination

1 … 605 606 607 … 669

Recent updates

  • CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus
  • Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study
  • Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
  • Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study
  • China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Others

Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law

Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.